VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 37.1% in November

VYNE Therapeutics Inc. (NASDAQ:VYNEGet Free Report) saw a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 64,300 shares, a drop of 37.1% from the November 15th total of 102,200 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average daily volume of 81,800 shares, the days-to-cover ratio is presently 0.8 days.

VYNE Therapeutics Price Performance

Shares of NASDAQ VYNE opened at $2.40 on Friday. The business has a 50-day moving average of $2.62 and a 200-day moving average of $2.20. The company has a market capitalization of $35.40 million, a price-to-earnings ratio of -2.79 and a beta of 1.37. VYNE Therapeutics has a 1-year low of $1.57 and a 1-year high of $3.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNEFree Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises approximately 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th largest position. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics at the end of the most recent quarter. Institutional investors own 83.78% of the company’s stock.

Analyst Ratings Changes

VYNE has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $5.75 target price on shares of VYNE Therapeutics in a research report on Friday, November 8th. BTIG Research initiated coverage on shares of VYNE Therapeutics in a research report on Monday, November 18th. They issued a “buy” rating and a $8.00 price objective for the company.

View Our Latest Report on VYNE

About VYNE Therapeutics

(Get Free Report)

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.

Read More

Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.